For the quarter ending 2025-09-30, EKSO made $4,227,000 in revenue. -$1,438,000 in net income. Net profit margin of -34.02%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 4,227,000 | 2,057,000 | 3,375,000 | 4,598,666.667 |
| Cost of revenue | 1,678,000 | 1,238,000 | 1,569,000 | 2,164,666.667 |
| Gross profit | 2,549,000 | 819,000 | 1,806,000 | 2,434,000 |
| Sales and marketing | 1,313,000 | 1,690,000 | 1,707,000 | 1,849,333.333 |
| Research and development | 550,000 | 852,000 | 988,000 | 1,032,333.333 |
| General and administrative | 2,088,000 | 2,252,000 | 2,551,000 | 2,159,333.333 |
| Total operating expenses | 3,951,000 | 4,794,000 | 5,246,000 | 5,041,000 |
| Loss from operations | -1,402,000 | -3,975,000 | - | - |
| Interest expense, net | 18,000 | 65,000 | 72,000 | 63,333.333 |
| Gain on revaluation of warrant liabilities | 0 | 0 | 1,000 | 153,333.333 |
| Loss on modification of warrant | 0 | 0 | - | -27,250 |
| Unrealized gain on foreign exchange | 4,000 | 1,339,000 | 626,000 | -533,000 |
| Other expense, net | -5,000 | -8,000 | -6,000 | 333.333 |
| Total other (expense) income, net | -19,000 | 1,266,000 | 549,000 | -479,000 |
| Net loss | -1,421,000 | -2,709,000 | -2,891,000 | -3,086,000 |
| Foreign currency translation adjustments | - | - | - | 442,666.667 |
| Other comprehensive loss | -17,000 | -1,107,000 | -533,000 | - |
| Comprehensive loss | -1,438,000 | -3,816,000 | -3,424,000 | -2,643,333.333 |
| Diluted average shares | - | - | - | -49,666.667 |
| Net loss per share applicable to common stockholders, basic and diluted (in dollars per share) | -0.54 | -1.24 | -0.12 | -0.153 |
| Us-gaap_earningspersharediluted | -0.54 | -1.24 | -0.12 | - |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 2,616,000 | 2,180,000 | 25,393,000 | -49,666.667 |
EKSO BIONICS HOLDINGS, INC. (EKSO)
EKSO BIONICS HOLDINGS, INC. (EKSO)